Unknown Manufacturer
AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.
AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.
AEOL 10150 shows the ability to scavenge a broad range of reactive oxygen species, or free radicals. As a catalytic antioxidant, AEOL 10150 mimics and thereby amplifies the body's natural enzymatic systems for eliminating these damaging compounds. Because oxygen-derived free radicals are believed to have an important role in the pathogenesis of many diseases, aeolus' catalytic antioxidants are believed to have a broad range of potential therapeutic uses.
Investigated for use/treatment in amyotrophic lateral sclerosis (ALS).
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
